Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nalbuphine + Dexmedetomidine Pretreatment for Remifentanil-Induced Postoperative Hyperalgesia
ChiCTR2100043215Phase 4Recruiting
- Sponsor
- Wuhu Second People's Hospital
- Start
- Feb 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of nalbuphine and dexmedetomidine in Remifentanil-induced hyperalgesia (RIH) (4 arms), sponsored by Wuhu Second People's Hospital. Primary endpoint: Pain threshold. Started Feb 2021; status: recruiting.
02
Drugs
nalbuphinedexmedetomidine
03
Conditions
Remifentanil-induced hyperalgesia (RIH)
Beyond the preview
Go deeper on ChiCTR2100043215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100043215.